Market Updates : Bharat Dynamics Ltd, Ceigall India Ltd, Inox Wind Ltd, Muthoot Finance Ltd, Zydus Lifesciences Ltd - ARETE Securities Ltd
Market Updates
The markets are expected to open marginally lower today as trends in GIFT NIFTY indicate a negative start for the broader index after NIFTY closed 3 points higher at 25,879 on Thursday.
Bharat Dynamics
The company received a Rs.2,095.70 crore order from the Indian Army for supplying Invar Anti-tank missiles to be executed over three years.
CESC
The company’s subsidiary CESC Green Power received in-principle approval to set up 3 GW solar, 5 GWh battery, and 60 MW captive power plant.
Ceigall India
The company emerged as H1 bidder for a Rs.12.19 crore Punjab water resources project to clear and de-silt the Satluj basin creek.
Fischer Medical Ventures
The company secured a Rs.9.29 crore order from Tamil Nadu Animal Husbandry for supplying and installing 65 digital radiography units.
Hi-Tech Pipes
The company laid the foundation for its Greenfield manufacturing project at Hindupur, A.P., advancing towards a 2 MTPA steel capacity target.
Inox Wind
The company secured a 100 MW order for supply of 3.3 MW turbines in Gujarat along with limited EPC and multi-year O&M services.
KP Green Engineering
The company signed a framework agreement with Senvion India to jointly develop up to 2 GW of wind and hybrid renewable projects across India.
Mahindra & Mahindra
The company formed a 50:50 JV with Manulife for a life insurance venture in India and acquired Mahindra Racing UK for Rs.14 crore through its subsidiary MOICML.
Muthoot Finance
The company approved Rs.500 crore equity infusion in subsidiary Muthoot Money to strengthen its capital base and improve capital adequacy ratio.
NBCC India
The company received a Rs.340.17 crore work order from Central University of Kashmir for Phase-I construction at Tulmulla, Ganderbal.
R Systems International
The company completed acquisition of 100% equity shares of Novigo Solutions, strengthening its digital transformation and technology service capabilities.
Zydus Lifesciences
The company received final USFDA approval for Diroximel Fumarate 231 mg delayed-release capsules, expanding its multiple sclerosis treatment portfolio and US market presence.
Please refer disclaimer at http://www.aretesecurities.com/
SEBI Regn. No.: INM0000127
